CHICAGO – Treatment with bisphosphonate therapy appears to be associated with an increased risk of atypical fractures of the femur, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.
"Current evidence suggests that there is an association between bisphosphonate therapy and atypical femoral fractures, but the extent of this risk remains unclear," according to Raphael P. H. Meier, M.D., and colleagues from University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland.